Journal Mobile Options
Table of Contents
Vol. 13, No. 5, 2010
Issue release date: June 2010
Public Health Genomic 2010;13:310–319
(DOI:10.1159/000253122)

Assessing the Potential Success of Cystic Fibrosis Carrier Screening: Lessons Learned from Tay-Sachs Disease and β-Thalassemia

Laberge A.-M. · Watts C. · Porter K. · Burke W.
aInstitute for Public Health Genetics and bDepartment of Health Services, School of Public Health and Community Medicine, University of Washington, and cDepartment of Bioethics and Humanities, School of Medicine, University of Washington, Seattle, Wash., USA; dMedical Genetics Division, Department of Pediatrics, Centre Hospitalier Universitaire Sainte-Justine, Université de Montréal, Montreal, Que., Canada

Individual Users: Register with Karger Login Information

Please create your User ID & Password





Contact Information











I have read the Karger Terms and Conditions and agree.

To view the fulltext, please log in

To view the pdf, please log in

Abstract

Objective: The objective of this study was to identify factors involved in the success of 2 well-established population-based carrier screening programs – Tay-Sachs disease (TSD) in Ashkenazi Jews and β-thalassemia in Sardinia and Cyprus – and to assess the potential for success of a population-based cystic fibrosis (CF) carrier screening strategy using these factors. Methods: We performed a literature review and key informant interviews. Results: Factors involved in the success of TSD and β-thalassemia carrier screening programs include disease characteristics (well-defined population at risk, severe disease with predictable course, availability of effective treatment), test characteristics (high sensitivity, straightforward interpretation of results), and community characteristics (involvement of community, support of families and advocacy groups, consensus in favor of avoiding affected births). Current CF screening strategies include few of the factors listed above. Unlike TSD and β-thalassemia, the purpose of current CF carrier screening strategies is informed reproductive decision-making, without an explicit goal of reducing disease incidence. Conclusion: When compared to TSD and β-thalassemia, CF is a less favorable candidate for population-based carrier screening. Because of its different purpose, CF carrier screening will require different measures of success than those used for TSD and β-thalassemia carrier screening, and a consensus on the value or success of CF carrier screening may be difficult to achieve.



Copyright / Drug Dosage

Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher or, in the case of photocopying, direct payment of a specified fee to the Copyright Clearance Center.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in goverment regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.

References

  1. Kaback MM, Nathan TJ, Greenwald S: Tay-Sachs disease: heterozygote screening and prenatal diagnosis – U.S. experience and world perspective. Prog Clin Biol Res 1977;18:13–36.
  2. Cao A, Rosatelli MC, Monni G, Galanello R: Screening for thalassemia: a model of success. Obstet Gynecol Clin North Am 2002;29:305–328.
  3. Kaback MM: Population-based genetic screening for reproductive counseling: the Tay-Sachs disease model. Eur J Pediatr 2000;159(suppl 3):S192–S195.
  4. Marx JL: The cystic fibrosis gene is found. Science 1989;245:923–925.
  5. Genetic testing for cystic fibrosis. NIH Consens Statement 1997;15:1–37.
  6. Richards CS, Bradley LA, Amos J, Allitto B, Grody WW, Maddalena A, McGinnis MJ, Prior TW, Popovich BW, Watson MS, Palomaki GE: Standards and guidelines for CFTR mutation testing. Genet Med 2002;4:379–391.
  7. Chodirker BN, Cadrin C, Davies GAL, Summers AM, Wilson RD, Winsor EJT, Young D: Canadian guidelines for prenatal diagnosis – genetic indications for prenatal diagnosis. J Soc Obstet Gynaecol Can 2001;23:525–531.
  8. Comité Consultatif National d’Ethique pour les sciences de la vie et de la santé. Le dépistage prénatal généralisé de la mucoviscidose. 2004. Report No. 83. Available at http://www.ccne-ethique.fr/docs/fr/avis083.pdf, accessed 08/28/09.
  9. Department of Health, National Screening Committee, UK: U.K. National Screening Committee – cystic fibrosis screening (in pregnancy). 2006. Available at http://www.screening.nhs.uk/cysticfibrosis-pregnancy, accessed 08/28/09.
  10. Murray J, Cuckle H, Taylor G, Littlewood J, Hewison J: Screening for cystic fibrosis. Health Technol Assess 1999;3:1–104.
  11. Morgan MA, Driscoll DA, Mennuti MT, Schulkin J: Practice patterns of obstetrician-gynecologists regarding preconception and prenatal screening for cystic fibrosis. Genet Med 2004;6:450–455.
  12. Morgan MA, Driscoll DA, Zinberg S, Schulkin J, Mennuti MT: Impact of self-reported familiarity with guidelines for cystic fibrosis carrier screening. Obstet Gynecol 2005;105:1355–1361.
  13. Zinberg RE, Kornreich R, Edelmann L, Desnick RJ: Prenatal genetic screening in the Ashkenazi Jewish population. Clin Perinatol 2001;28:367–382.
  14. Kaback MM, Desnick RJ: Tay-Sachs disease: from clinical description to molecular defect. Adv Genet 2001;44:1–9.
  15. Modell B, Khan M, Darlison M: Survival in beta-thalassaemia major in the UK: data from the UK Thalassaemia Register. Lancet 2000;355:2051–2052.
  16. Olivieri NF: The beta-thalassemias. N Engl J Med 1999;341:99–109.
  17. Cao A: Results of programmes for antenatal detection of thalassemia in reducing the incidence of the disorder. Blood Rev 1987;1:169–176.
  18. Angastiniotis MA, Hadjiminas MG: Prevention of thalassaemia in Cyprus. Lancet 1981;1:369–371.
  19. O’Brien JS, Okada S, Chen A, Fillerup DL: Tay-Sachs disease. Detection of heterozygotes and homozygotes by serum hexosaminidase assay. N Engl J Med 1970;283:15–20.
  20. Triggs-Raine BL, Feigenbaum AS, Natowicz M, Skomorowski MA, Schuster SM, Clarke JT, Mahuran DJ, Kolodny EH, Gravel RA: Screening for carriers of Tay-Sachs disease among Ashkenazi Jews. A comparison of DNA-based and enzyme-based tests. N Engl J Med 1990;323:6–12.
  21. Fernandes MJ, Kaplan F, Clow CL, Hechtman P, Scriver CR: Specificity and sensitivity of hexosaminidase assays and DNA analysis for the detection of Tay-Sachs disease gene carriers among Ashkenazic Jews. Genet Epidemiol 1992;9:169–175.
  22. Cao A: Carrier screening and genetic counselling in beta-thalassemia. Int J Hematol 2002;76(suppl 2):105–113.
  23. Guterman L: Choosing eugenics: how far will nations go to eliminate a genetic disease? Chron High Educ 2003;49:A22–A24, A26.

    External Resources

  24. Cao A, Furbetta M, Galanello R, Melis MA, Angius A, Ximenes A, Rosatelli C, Ruggeri R, Addis M, Tuveri T, Falchi AM, Paglietti E, Scalas MT: Prevention of homozygous beta-thalassemia by carrier screening and prenatal diagnosis in Sardinia. Am J Hum Genet 1981;33:592–605.
  25. Cao A, Rosatelli C, Galanello R, Monni G, Olla G, Cossu P, Ristaldi MS: The prevention of thalassemia in Sardinia. Clin Genet 1989;36:277–285.
  26. Mitchell JJ, Capua A, Clow C, Scriver CR: Twenty-year outcome analysis of genetic screening programs for Tay-Sachs and beta-thalassemia disease carriers in high schools. Am J Hum Genet 1996;59:793–798.
  27. Kaback MM: Screening and prevention in Tay-Sachs disease: origins, update, and impact. Adv Genet 2001;44:253–265.
  28. Cao A, Saba L, Galanello R, Rosatelli MC: Molecular diagnosis and carrier screening for beta thalassemia. Jama 1997;278:1273–1277.
  29. Cowan RS: Heredity and Hope: The Case for Genetic Screening. Cambridge, Harvard University Press, 2008, p 292.
  30. Ekstein J, Katzenstein H: The Dor Yeshorim story: community-based carrier screening for Tay-Sachs disease. Adv Genet 2001;44:297–310.
  31. Kornreich R, Ekstein J, Edelmann L, Desnick RJ: Premarital and prenatal screening for cystic fibrosis: experience in the Ashkenazi Jewish population. Genet Med 2004;6:415–420.
  32. Modell B, Khan M, Darlison M, King A, Layton M, Old J, Petrou M, Varnavides L: A national register for surveillance of inherited disorders: beta thalassaemia in the United Kingdom. Bull World Health Organ 2001;79:1006–1013.
  33. Statement of the American Society of Human Genetics on cystic fibrosis carrier screening. Am J Hum Genet 1992;51:1443–1444.
  34. Mennuti MT: Lights! Camera! Action! Obstet Gynecol 2001;98:539–541.
  35. Cystic Fibrosis Foundation: Patient Registry Annual Data Report 2007. Available at http://www.cff.org/UploadedFiles/research/ClinicalResearch/2007-Patient-Registry-Report.pdf, accessed 08/28/09.
  36. Lai HJ, Cheng Y, Farrell PM: The survival advantage of patients with cystic fibrosis diagnosed through neonatal screening: evidence from the United States Cystic Fibrosis Foundation registry data. J Pediatr 2005;147(suppl 3):S57–S63.
  37. Ratjen F, Doring G: Cystic fibrosis. Lancet 2003;361:681–689.
  38. FitzSimmons SC: The changing epidemiology of cystic fibrosis. J Pediatr 1993;122: 1–9.
  39. Rigoli L, Meo A, Miceli MR, Alessio K, Caruso RA, La Rosa MA, Salpietro DC, Ricca M, Barberi I: Molecular analysis of beta-thalassaemia patients in a high incidence area of southern Italy. Clin Lab Haematol 2001;23:373–378.
  40. Salvatore F, Scudiero O, Castaldo G: Genotype-phenotype correlation in cystic fibrosis: the role of modifier genes. Am J Med Genet 2002;111:88–95.
  41. Davis PB: Cystic fibrosis since 1938. Am J Respir Crit Care Med 2006;173:475–482.
  42. Super M, Abbott J: Genetic advances in cystic fibrosis: to screen, to treat or both? Disabil Rehabil 1998;20:202–208.
  43. Grosse SD, Boyle CA, Botkin JR, Comeau AM, Kharrazi M, Rosenfeld M, Wilfond BS; CDC: Newborn screening for cystic fibrosis: evaluation of benefits and risks and recommendations for state newborn screening programs. MMWR Recomm Rep 2004;53:1–36.

    External Resources

  44. Rosenfeld M: Overview of published evidence on outcomes with early diagnosis from large US observational studies. J Pediatr 2005;147(suppl 3):S11–S14.
  45. Monaghan KG, Highsmith WE, Amos J, Pratt VM, Roa B, Friez M, Pike-Buchanan LL, Buyse IM, Redman JB, Strom CM, Young AL, Sun W: Genotype-phenotype correlation and frequency of the 3199del6 cystic fibrosis mutation among I148T carriers: results from a collaborative study. Genet Med 2004;6:421–425.
  46. Watson MS, Cutting GR, Desnick RJ, Driscoll DA, Klinger K, Mennuti M, Palomaki GE, Popovich BW, Pratt VM, Rohlfs EM, Strom CM, Richards CS, Witt DR, Grody WW: Cystic fibrosis population carrier screening: 2004 revision of American College of Medical Genetics mutation panel. Genet Med 2004;6:387–391.
  47. Palomaki GE, FitzSimmons SC, Haddow JE: Clinical sensitivity of prenatal screening for cystic fibrosis via CFTR carrier testing in a United States panethnic population. Genet Med 2004;6:405–414.
  48. ACOG committee opinion. Number 298, August 2004. Prenatal and preconceptional carrier screening for genetic diseases in individuals of Eastern European Jewish descent. Obstet Gynecol 2004;104:425–428.

    External Resources

  49. Cystic Fibrosis Foundation: Testing for cystic fibrosis – genetic carrier testing. Available at http://www.cff.org/AboutCF/Testing/GeneticCarrierTest/, accessed 08/28/09.
  50. Doherty RA, Palomaki GE, Kloza EM, Erickson JL, Haddow JE: Couple-based prenatal screening for cystic fibrosis in primary care settings. Prenat Diagn 1996;16:397–404.
  51. Witt DR, Schaefer C, Hallam P, Wi S, Blumberg B, Fishbach A, Holtzman J, Kornfeld S, Lee R, Nemzer L, Palmer R: Cystic fibrosis heterozygote screening in 5,161 pregnant women. Am J Hum Genet 1996;58:823–835.
  52. Grody WW, Dunkel-Schetter C, Tatsugawa ZH, Fox MA, Fang CY, Cantor RM, Novak JM, Bass HN, Crandall BF: PCR-based screening for cystic fibrosis carrier mutations in an ethnically diverse pregnant population. Am J Hum Genet 1997;60:935–947.
  53. Mischler EH, Wilfond BS, Fost N, Laxova A, Reiser C, Sauer CM, Makholm LM, Shen G, Feenan L, McCarthy C, Farrell PM: Cystic fibrosis newborn screening: impact on reproductive behavior and implications for genetic counseling. Pediatrics 1998;102:44–52.
  54. Wei S, Quigg MH, Monaghan KG: Is cystic fibrosis carrier screening cost effective? Community Genet 2007;10:103–109.
  55. Hale JE, Parad RB, Comeau AM: Newborn screening showing decreasing incidence of cystic fibrosis. N Engl J Med 2008;358:973–974.
  56. Mennie ME, Gilfillan A, Compton M, Curtis L, Liston WA, Pullen I, Whyte DA, Brock DJ: Prenatal screening for cystic fibrosis. Lancet 1992;340:214–216.
  57. Brock DJ: Prenatal screening for cystic fibrosis: 5 years’ experience reviewed. Lancet 1996;347:148–150.
  58. Nielsen R, Gyrd-Hansen D: Prenatal screening for cystic fibrosis: an economic analysis. Health Econ 2002;11:285–299.
  59. Brambati B, Tului L, Fattore S: First-trimester fetal screening of cystic fibrosis in low-risk population. Lancet 1993;342:624.
  60. Livingstone J, Axton RA, Gilfillan A, Mennie M, Compton M, Liston WA, Calder AA, Gordon AJ, Brock DJ: Antenatal screening for cystic fibrosis: a trial of the couple model. BMJ 1994;308:1459–1462.
  61. Miedzybrodzka ZH, Hall MH, Mollison J, Templeton A, Russell IT, Dean JC, Kelly KF, Marteau TM, Haites NE: Antenatal screening for carriers of cystic fibrosis: randomised trial of stepwise v couple screening. BMJ 1995;310:353–357.
  62. Clausen H, Brandt NJ, Schwartz M, Skovby F: Psychological and social impact of carrier screening for cystic fibrosis among pregnant women – a pilot study. Clin Genet 1996;49:200–205.
  63. Scotet V, Audrezet MP, Roussey M, Rault G, Blayau M, De Braekeleer M, Ferec C: Impact of public health strategies on the birth prevalence of cystic fibrosis in Brittany, France. Hum Genet 2003;113:280–285.
  64. Lane B, Williamson P, Dodge JA, Harris H, Super M, Harris R: Confidential inquiry into families with two siblings with cystic fibrosis. Arch Dis Child 1997;77:501–503.
  65. Borgo G, Fabiano T, Perobelli S, Mastella G: Effect of introducing prenatal diagnosis on the reproductive behaviour of families at risk for cystic fibrosis. A cohort study. Prenat Diagn 1992;12:821–830.
  66. Boue J, Muller F, Simon-Bouy B, Faure C, Boue A: Consequences of prenatal diagnosis of cystic fibrosis on the reproductive attitudes of parents of affected children. Prenat Diagn 1991;11:209–214.
  67. Baranov VS, Gorbunova VN, Ivaschenko TE, Shwed N, Osinovskaya NS, Kascheeva TK, Lebedev VM, Mikhailov AV, Vakharlovsky VG, Kuznetzova TV: Five years’ experience of prenatal diagnosis of cystic fibrosis in the former U.S.S.R. Prenat Diagn 1992;12:575–586.
  68. Super M, Schwarz MJ: Mutations of the cystic fibrosis gene locus within the population of the Northwest of England. Eur J Pediatr 1992;151:108–111.
  69. Super M, Schwarz MJ, Malone G, Roberts T, Haworth A, Dermody G: Active cascade testing for carriers of cystic fibrosis gene. BMJ 1994;308:1462–1467.
  70. Casals T, Gimenez J, Ramos MD, Nunes V, Estivill X: Prenatal diagnosis of cystic fibrosis in a highly heterogeneous population. Prenat Diagn 1996;16:215–222.
  71. Dudding T, Wilcken B, Burgess B, Hambly J, Turner G: Reproductive decisions after neonatal screening identifies cystic fibrosis. Arch Dis Child Fetal Neonatal Ed 2000;82:F124–F127.
  72. Henneman L, Bramsen I, Van Os TA, Reuling IE, Heyerman HG, van der Laag J, van der Ploeg HM, ten Kate LP: Attitudes towards reproductive issues and carrier testing among adult patients and parents of children with cystic fibrosis (CF). Prenat Diagn 2001;21:1–9.
  73. Henneman L, Kooij L, Bouman K, ten Kate LP: Personal experiences of cystic fibrosis (CF) carrier couples prospectively identified in CF families. Am J Med Genet 2002;110:324–331.
  74. Wilfond BS, Parad RB, Fost N: Balancing benefits and risks for cystic fibrosis newborn screening: implications for policy decisions. J Pediatr 2005;147(suppl 3):S109–S113.
  75. Farrell PM, Lai HJ, Li Z, Kosorok MR, Laxova A, Green CG, Collins J, Hoffman G, Laessig R, Rock MJ, Splaingard ML: Evidence on improved outcomes with early diagnosis of cystic fibrosis through neonatal screening: enough is enough! J Pediatr 2005;147(suppl 3):S30–S36.
  76. Cystic Fibrosis Foundation: Testing for cystic fibrosis – Newborn Screening. Available at http://www.cff.org/AboutCF/Testing/NewbornScreening/, accessed 08/28/09.
  77. Pletcher BA, Gross SJ, Monaghan KG, Driscoll DA, Watson MS: The future is now: carrier screening for all populations. Genet Med 2008;10:33–36.


Pay-per-View Options
Direct payment This item at the regular price: USD 38.00
Payment from account With a Karger Pay-per-View account (down payment USD 150) you profit from a special rate for this and other single items.
This item at the discounted price: USD 26.50